Application of antisense conjugates for the treatment of myotonic dystrophy type 1
Myotonic dystrophy type 1 (DM1) is one of the most common muscular dystrophies and can be potentially treated with antisense therapy decreasing mutant DMPK, targeting miRNAs or their binding sites or via a blocking mechanism for MBNL1 displacement from the repeats. Unconjugated antisense molecules a...
| Main Authors: | , , , , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado: |
MDPI
2023
|